Drug
Degarelix clinical trials
Also written Firmagon, FE200486 and ASP3550.
- studies test it
- 85
- open now
- 5
- in phase 3
- 29
- first study started
- 2001
Keep track of what changes. Save the degarelix studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Firmagon
- 38
Studies by the year they started
84 studies that test it; most in 2012 (11)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 11 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 45
- Phase 3
- 29
- Phase 4
- 5
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 40 · Other 45
Ferring Pharmaceuticals (37) · Memorial Sloan Kettering Cancer Center (6) · Astellas Pharma Inc (3) · Centre for Endocrinology and Reproductive Medicine, Italy (2) · University of Washington (2) · British Columbia Cancer Agency (2) · Rabin Medical Center (2) · University Health Network, Toronto (2)
Often tested with
Tested in the same studies.
Leuprolide (9) · Triptorelin (7) · Goserelin (6) · Bicalutamide (5) · Docetaxel (4) · Abiraterone Acetate (4) · Abiraterone (4) · Darolutamide (3)
Studies
Open first, then newest update. How each study uses degarelix is read from its arms, and is right about nine times in ten.
Testing it · 85
- ETHAN - ET for Male BCRecruitingPhase 2Jose Pablo LeoneNCT05501704Written as Degarelix
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingPhase 2Baptist Health South FloridaNCT07455903Written as Degarelix
- NeoAdjuvant Theranostic Lutetium Study: The Nautilus TrialRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06066437Written as Arm B: 177Lu rhPSMA-10.1 plus Degarelix
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersRecruitingPhase 2/3Cancer Research AntwerpNCT06282588Written as Firmagon 120 MG Injection
- Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerNot yet recruitingPhase 2University Health Network, TorontoNCT04176081Written as Degarelix
- Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate CancerActive, not recruitingPhase 1Turku University HospitalNCT05917860Written as Degarelix
- A Study of BMS986365 in Combination With Degarelix in People With Prostate CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07335796Written as Degarelix
- Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)WithdrawnPhase 2British Columbia Cancer AgencyNCT01630967Written as Degarelix
- TRial on the Endocrine Activity of Neoadjuvant DegarelixCompletedPhase 2ETOP IBCSG Partners FoundationNCT02005887Written as degarelix
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingPhase 3NRG OncologyNCT05050084Written as Degarelix
- Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate CancerCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT01542021Written as degarelix injection
- High-Dose Brachytherapy in Treating Patients With Prostate CancerCompletedNot applicableStanford UniversityNCT02346253Written as Degarelix
- Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate CancerActive, not recruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT02799706Written as Degarelix
- Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate CancerActive, not recruitingPhase 2City of Hope Medical CenterNCT03361735Written as Degarelix
- Targeting Androgen Signaling in Urothelial Cell Carcinoma - NeoadjuvantTerminatedPhase 1Brown UniversityNCT05839119Written as Degarelix
- Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast CancerCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT03947151Written as Degarelix injection(s)
- Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT01746849Written as Degarelix
- Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate CancerCompletedPhase 2/3Ferring PharmaceuticalsNCT00117286Written as Degarelix
- Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.CompletedPhase 2Medical University of South CarolinaNCT03069937Written as Degarelix
- Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic AdenocarcinomaCompletedPhase 2Centre Leon BerardNCT04391556Written as Firmagon
See all 85 studies that test degarelix →
Given in every arm · 24 — degarelix is usual care beside what is tested
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT05873192Written as Degarelix
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT03678025Written as Degarelix
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04423211Written as Degarelix
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingPhase 2City of Hope Medical CenterNCT04734730Written as Degarelix
- Cardiometabolic Consequences of the Loss of Ovarian FunctionRecruitingPhase 4University of Colorado, DenverNCT06264882Written as Degarelix
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerActive, not recruitingPhase 2/3VA Office of Research and DevelopmentNCT04787744Written as Degarelix & Relugolix
- Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)CompletedPhase 1/2Mark SteinNCT03689699Written as Degarelix
- Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerTerminatedPhase 1Praful Ravi, MB BCHir, MRCPNCT05617885Written as Degarelix
- Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate CancerActive, not recruitingPhase 1/2University of Wisconsin, MadisonNCT04989946Written as Degarelix
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryActive, not recruitingPhase 2/3NRG OncologyNCT03070886Written as Degarelix
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialActive, not recruitingPhase 3NRG OncologyNCT04513717Written as Degarelix
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT01786265Written as Degarelix
- Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical ProstatectomyCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT02020070Written as Degarelix
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT04455750Written as Degarelix
- Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerActive, not recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT01990196Written as degarelix
- REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate CancerActive, not recruitingPhase 2Mark SteinNCT03951831Written as Degarelix
- Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical ProstatectomyActive, not recruitingPhase 2Universitaire Ziekenhuizen KU LeuvenNCT03080116Written as Degarelix
- Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate CancerCompletedEarly Phase 1University of Wisconsin, MadisonNCT03358563Written as Degarelix
- Ipilimumab + Androgen Depravation Therapy in Prostate CancerTerminatedPhase 2M.D. Anderson Cancer CenterNCT01377389Written as Degarelix
- Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate CancerCompletedNot applicableSidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02489357Written as Degarelix
Showing 20 of 24.
As the comparator · 4 — what is tested is compared with degarelix
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as Degarelix
- Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPRecruitingPhase 2Cancer Research AntwerpNCT03899077Written as Degarelix acetate
- Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate CancerCompletedPhase 2University of Colorado, DenverNCT02278185Written as degarelix
- Safety and Efficacy of TAK-385 for Patients With Localized Prostate CancerCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT02135445Written as Degarelix
Codes
What other systems call degarelix · ClinicalTrials.gg INT004362
- UNII (FDA) SX0XJI3A11DEGARELIXConfirmed FDA, Wikidata
- RxNorm 475230Confirmed FDA, Wikidata
- Wikidata Q1182795degarelixConfirmed FDA, Wikidata
- NCI Thesaurus C48385DegarelixConfirmed FDA, Wikidata
- DrugBank DB06699One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SX0XJI3A11 | DEGARELIX | Confirmed FDA, Wikidata |
| RxNorm | 475230 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1182795 | degarelix | Confirmed FDA, Wikidata |
| NCI Thesaurus | C48385 | Degarelix | Confirmed FDA, Wikidata |
| DrugBank | DB06699 | — | One source Wikidata |
Also registered as degarelix acetate (UNII I18S89P20R · RxNorm 835863).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.